Imunopharm Technology Co., Ltd.

Imunopharm is a clinical-stage biopharmaceutical company founded in Beijing in 2015. Committed to the mission to cure the incurable, Imunopharm focuses on applying innovative cell and gene therapies to help patients prevail over serious diseases such as cancer and autoimmune disorders. Imunopharm has established an integrated autonomous platform required for the research and industrialization. Our pipeline covers hematologic malignancies such as lymphoma, leukemia, and multiple myeloma, as well as solid tumors including liver cancer and colorectal cancer. Clinical data of CAR-T products have been presented multiple times at international conferences such as ASCO, ASH, IMS, and ESMO. Additionally, our in-house developed CAR-T therapy product, IM96, targeting GUCY2C for the treatment of late-stage metastatic colorectal cancer, has demonstrated groundbreaking efficacy and safety data in early clinical trials. We believe IM96 is a potential FIC therapy for late stage CRC. To date, Imunopharm has completed 9 rounds of strategic financing, and has obtained the CAR-T drug production license with 5 China INDs. At present, Imunopharm has emerged as a cornerstone in CAR-T therapy in China.